REGENXBIO is a biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
REGENXBIO news
05.05.2022
REGENXBIO's GAAP loss for 3 months of 2022 was $76.723 million, up 53% from $50.139 million in the prior year. Revenue increased 17.7% to $22.218 million from $18.884 million a year earlier.
Source: 
ir.regenxbio.com
ir.regenxbio.com
02.03.2022
Net income of REGENXBIO under GAAP for 2021 was $127.84 million, compared to a loss of $111.25 million in the previous year. Revenue tripled to $470.347 million from $154.567 million a year earlier.
Source: 
regenxbio.gcs-web.com
regenxbio.gcs-web.com
03.11.2021
REGENXBIO posted a GAAP loss of $166.183 million for 9M 2021, up 2.6 times from $65.009 million in the previous year. Revenues decreased by 46.1% to $71.692 million from $133.122 million a year earlier.
Source: regenxbio.gcs-web.com
regenxbio.gcs-web.com
10.08.2021
REGENXBIO's GAAP loss for 6M 2021 was $107.778 million, up 46% from $73.8 million in the previous year. Revenue increased 19.6% to $40.919 million from $34.21 million a year earlier.
Source: regenxbio.gcs-web.com
regenxbio.gcs-web.com
General information
| Company name | REGENXBIO |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 9600 BLACKWELL ROAD SUITE 210 ROCKVILLE MD 20850 240-552-8181 |
| Mailing address | 9600 BLACKWELL ROAD SUITE 210 ROCKVILLE MD 20850 |
| Website | www.regenxbio.com |
| Information disclosure | www.sec.gov |
English (US) 